Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tumor mutational burden is a determinant of immune-mediated survival in breast cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2018-07-31
DOI
10.1080/2162402x.2018.1490854
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer
- (2017) Thomas Karn et al. JAMA Oncology
- Conservation of immune gene signatures in solid tumors and prognostic implications
- (2016) Julia Chifman et al. BMC CANCER
- The genomic landscape of breast cancer and its interaction with host immunity
- (2016) Stephen Luen et al. BREAST
- Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer
- (2016) Janice M. Mehnert et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
- (2016) Michael D. Iglesia et al. JNCI-Journal of the National Cancer Institute
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- (2016) N. McGranahan et al. SCIENCE
- The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes
- (2016) Bernard Pereira et al. Nature Communications
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types
- (2016) Michael D. Iglesia et al. JNCI-Journal of the National Cancer Institute
- Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness
- (2016) L. D. Miller et al. Cancer Immunology Research
- Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
- (2016) Vassiliki Kotoula et al. PLoS One
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity
- (2015) Michael S. Rooney et al. CELL
- Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
- (2015) Giovanni Ciriello et al. CELL
- Prognostic and predictive immune gene signatures in breast cancer
- (2015) Davide Bedognetti et al. CURRENT OPINION IN ONCOLOGY
- Robust enumeration of cell subsets from tissue expression profiles
- (2015) Aaron M Newman et al. NATURE METHODS
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data
- (2014) Svasti Haricharan et al. BREAST CANCER RESEARCH AND TREATMENT
- Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
- (2014) S. D. Brown et al. GENOME RESEARCH
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dual roles for immune metagenes in breast cancer prognosis and therapy prediction
- (2014) Angela Alistar et al. Genome Medicine
- GSVA: gene set variation analysis for microarray and RNA-Seq data
- (2013) Sonja Hänzelmann et al. BMC BIOINFORMATICS
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
- (2013) Fernando Ulloa-Montoya et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Systematic Analysis of Challenge-Driven Improvements in Molecular Prognostic Models for Breast Cancer
- (2013) A. A. Margolin et al. Science Translational Medicine
- Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
- (2013) Srikanth Nagalla et al. GENOME BIOLOGY
- DNA Mismatch Repair Deficiency in Breast Carcinoma
- (2012) Yong H. Wen et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- The draft genome and transcriptome of Cannabis sativa
- (2011) Harm van Bakel et al. GENOME BIOLOGY
- Supervised normalization of microarrays
- (2010) Brigham H. Mecham et al. BIOINFORMATICS
- A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
- (2010) T. O. Nielsen et al. CLINICAL CANCER RESEARCH
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- Control of granzymes by serpins
- (2009) D Kaiserman et al. CELL DEATH AND DIFFERENTIATION
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More